Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
5.63M
-
Shares change
-
-3.85M
-
Total reported value, excl. options
-
$6.58M
-
Value change
-
-$4.8M
-
Put/Call ratio
-
0.04
-
Number of buys
-
38
-
Number of sells
-
-39
-
Price
-
$1.17
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2024
92 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q2 2024.
Protalix BioTherapeutics, Inc. - COM (PLX) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.63M shares
.
Largest 10 shareholders include MILLENNIUM MANAGEMENT LLC (811K shares), RENAISSANCE TECHNOLOGIES LLC (805K shares), GOLDMAN SACHS GROUP INC (462K shares), NORTHERN TRUST CORP (423K shares), GSA CAPITAL PARTNERS LLP (401K shares), BlackRock Inc. (333K shares), JANE STREET GROUP, LLC (290K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (184K shares), Y-Intercept (Hong Kong) Ltd (158K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (158K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.